CA2044590A1 - Anticorps a10 hybride souris-homme specifique d'un antigene associe aux cellules tumorales chez l'homme - Google Patents
Anticorps a10 hybride souris-homme specifique d'un antigene associe aux cellules tumorales chez l'hommeInfo
- Publication number
- CA2044590A1 CA2044590A1 CA002044590A CA2044590A CA2044590A1 CA 2044590 A1 CA2044590 A1 CA 2044590A1 CA 002044590 A CA002044590 A CA 002044590A CA 2044590 A CA2044590 A CA 2044590A CA 2044590 A1 CA2044590 A1 CA 2044590A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- fragment
- chain
- derivative
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43501289A | 1989-11-13 | 1989-11-13 | |
US435,012 | 1989-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2044590A1 true CA2044590A1 (fr) | 1991-05-14 |
Family
ID=23726623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002044590A Abandoned CA2044590A1 (fr) | 1989-11-13 | 1990-11-13 | Anticorps a10 hybride souris-homme specifique d'un antigene associe aux cellules tumorales chez l'homme |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0457875A4 (fr) |
JP (1) | JPH03206886A (fr) |
KR (1) | KR910009284A (fr) |
AU (1) | AU634314B2 (fr) |
CA (1) | CA2044590A1 (fr) |
WO (1) | WO1991007418A1 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645493B1 (en) * | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
US5641751A (en) * | 1995-05-01 | 1997-06-24 | Centocor, Inc. | Tumor necrosis factor inhibitors |
AU2610097A (en) * | 1996-04-10 | 1997-10-29 | Sangstat Medical Corporation | Cytomodulating conjugates of members of specific binding pairs |
IT1289608B1 (it) * | 1997-02-05 | 1998-10-15 | Angelini Ricerche Spa | Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
JP5059271B2 (ja) | 2000-03-31 | 2012-10-24 | パーデュー・リサーチ・ファウンデイション | リガンド免疫原複合体を用いる処置方法 |
WO2003062370A2 (fr) | 2001-07-19 | 2003-07-31 | Perlan Therapeutics, Inc. | Proteines multimeres et methodes de production et d'utilisation de ces proteines |
KR20040106547A (ko) | 2002-05-15 | 2004-12-17 | 엔도사이트, 인코포레이티드 | 비타민-마이토마이신 공액체 |
ES2395082T3 (es) | 2003-01-27 | 2013-02-08 | Endocyte, Inc. | Conjugado de folato-vinblastina como medicamento |
WO2006012527A1 (fr) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Groupes de liaison bivalents et conjugués de ceux-ci |
ES2468240T3 (es) | 2005-08-19 | 2014-06-16 | Endocyte, Inc. | Conjugados de ligando de múltiples fármacos |
WO2007022493A2 (fr) | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Conjugues de ligand d'alcaloides vinca, analogues et derives |
WO2007092299A2 (fr) | 2006-02-03 | 2007-08-16 | Purdue Research Foundation | Conjugués ciblés et radiation |
EP2489372A3 (fr) | 2007-03-14 | 2013-01-02 | Endocyte, Inc. | Conjugués de tubulysines d'administration de médicament liés à un ligand de liaison |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
CA2690943A1 (fr) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugues contenant des lieurs espaceurs hydrophiles |
JP2010536790A (ja) | 2007-08-17 | 2010-12-02 | パーデュー・リサーチ・ファウンデーション | Psma結合性リガンド−リンカー結合体及び使用方法 |
JP2011500835A (ja) | 2007-10-25 | 2011-01-06 | エンドサイト,インコーポレイテッド | チューブリシン類および調製プロセス |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
WO2013050453A1 (fr) | 2011-10-07 | 2013-04-11 | Baxter Healthcare S.A. | Oxmif en tant que marqueur de diagnostic |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
WO2014062697A2 (fr) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Conjugués d'administration de médicament contenant des acides aminés artificiels et procédés d'utilisation |
BR112015011118B1 (pt) | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
RS65324B1 (sr) | 2013-10-18 | 2024-04-30 | Novartis Ag | Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
EP3268046A4 (fr) | 2015-03-13 | 2018-11-21 | Endocyte, Inc. | Conjugués pour le traitement de maladies |
MX2023012114A (es) | 2021-04-16 | 2023-10-24 | Novartis Ag | Agentes radioterapeuticos dirigidos al receptor de folato y su uso. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
AU625613B2 (en) * | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
GB8800078D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel antibodies |
IL89489A0 (en) * | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
-
1990
- 1990-11-13 AU AU66641/90A patent/AU634314B2/en not_active Ceased
- 1990-11-13 JP JP2308453A patent/JPH03206886A/ja active Pending
- 1990-11-13 WO PCT/US1990/006620 patent/WO1991007418A1/fr not_active Application Discontinuation
- 1990-11-13 EP EP19910900650 patent/EP0457875A4/en not_active Withdrawn
- 1990-11-13 KR KR1019900018568A patent/KR910009284A/ko not_active Application Discontinuation
- 1990-11-13 CA CA002044590A patent/CA2044590A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPH03206886A (ja) | 1991-09-10 |
KR910009284A (ko) | 1991-06-28 |
AU634314B2 (en) | 1993-02-18 |
EP0457875A4 (en) | 1993-03-03 |
AU6664190A (en) | 1991-05-23 |
EP0457875A1 (fr) | 1991-11-27 |
WO1991007418A1 (fr) | 1991-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU634314B2 (en) | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen | |
US6461824B1 (en) | Production of chimeric antibodies with specificity to human tumor antigens | |
US5843685A (en) | Production of chimeric mouse-human antibodies with specificity to human tumor antigens | |
US5721108A (en) | Chimeric antibody with specificity to human B cell surface antigen | |
AU626254B2 (en) | Chimeric antibody with specificity to human tumor antigen | |
EP0731167B1 (fr) | Assemblage modulaire de gènes d'anticorps, anticorps ainsi préparés et leurs utilisations | |
US6893625B1 (en) | Chimeric antibody with specificity to human B cell surface antigen | |
AU606320B2 (en) | Modular assembly of antibody genes, antibodies prepared thereby and use | |
US5576195A (en) | Vectors with pectate lyase signal sequence | |
US5618920A (en) | Modular assembly of antibody genes, antibodies prepared thereby and use | |
CA2019323A1 (fr) | Anticorps km10 chimeriques humain - murin specifiques contre un antigene de cellules tumorales humaines | |
US20050196400A1 (en) | Production of chimeric mouse-human antibodies with specificity to human tumor antigens | |
AU606653C (en) | Chimeric antibody with specificity to human B cell surface antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |